pubmed-article:10980656 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:10980656 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
pubmed-article:10980656 | lifeskim:mentions | umls-concept:C0242852 | lld:lifeskim |
pubmed-article:10980656 | lifeskim:mentions | umls-concept:C0623362 | lld:lifeskim |
pubmed-article:10980656 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:10980656 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
pubmed-article:10980656 | lifeskim:mentions | umls-concept:C0919273 | lld:lifeskim |
pubmed-article:10980656 | lifeskim:mentions | umls-concept:C0205365 | lld:lifeskim |
pubmed-article:10980656 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:10980656 | pubmed:dateCreated | 2000-10-10 | lld:pubmed |
pubmed-article:10980656 | pubmed:abstractText | To determine the efficacy of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinase, in the treatment of experimental proliferative vitreoretinopathy (PVR) induced by intravitreal dispase injection. | lld:pubmed |
pubmed-article:10980656 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10980656 | pubmed:language | eng | lld:pubmed |
pubmed-article:10980656 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10980656 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:10980656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10980656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10980656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10980656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10980656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10980656 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:10980656 | pubmed:month | Jun | lld:pubmed |
pubmed-article:10980656 | pubmed:issn | 0271-3683 | lld:pubmed |
pubmed-article:10980656 | pubmed:author | pubmed-author:ChengLL | lld:pubmed |
pubmed-article:10980656 | pubmed:author | pubmed-author:AppeltKK | lld:pubmed |
pubmed-article:10980656 | pubmed:author | pubmed-author:FreemanW RWR | lld:pubmed |
pubmed-article:10980656 | pubmed:author | pubmed-author:Bergeron-Lynn... | lld:pubmed |
pubmed-article:10980656 | pubmed:author | pubmed-author:KeefeKK | lld:pubmed |
pubmed-article:10980656 | pubmed:author | pubmed-author:McDermottC... | lld:pubmed |
pubmed-article:10980656 | pubmed:author | pubmed-author:OzerdemUU | lld:pubmed |
pubmed-article:10980656 | pubmed:author | pubmed-author:Chaidhawangul... | lld:pubmed |
pubmed-article:10980656 | pubmed:author | pubmed-author:Mach-HofacreB... | lld:pubmed |
pubmed-article:10980656 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:10980656 | pubmed:volume | 20 | lld:pubmed |
pubmed-article:10980656 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:10980656 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:10980656 | pubmed:pagination | 447-53 | lld:pubmed |
pubmed-article:10980656 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:meshHeading | pubmed-meshheading:10980656... | lld:pubmed |
pubmed-article:10980656 | pubmed:year | 2000 | lld:pubmed |
pubmed-article:10980656 | pubmed:articleTitle | The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. | lld:pubmed |
pubmed-article:10980656 | pubmed:affiliation | Shiley Eye Center, University of California, San Diego, California 92093-0946, United States of America. | lld:pubmed |
pubmed-article:10980656 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:10980656 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:10980656 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10980656 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10980656 | lld:pubmed |